Page 340 - Glucose Monitoring Devices

References 347

only one system is currently approved by regulatory bodies, it is anticipated a
number of systems will soon come to market and DIY systems will become
commercially available. In the end, the technology that will most help a person
with diabetes is the one he/she chooses to use; therefore, continued innovation
and choice will be critical to allow uptake and successful use of these devices. There
is great hope that future closed-loop therapies are likely to continue to improve
psychological and physiological outcomes for those with T1D.

Short biography
Laura Nally (short biography): Dr. Nally is an Instructor at Yale University School of
Medicine. She completed medical school at UC Davis School of Medicine, pediat-
rics residency training at Children’s Hospital of Orange County, and pediatric
endocrinology fellowship at Stanford University. Jennifer Sherr (short biography):
Dr. Sherr is an Associate Professor at Yale University School of Medicine.
Following her diagnosis of type 1 diabetes in 1987, Dr. Sherr decided to pursue a
career in pediatric endocrinology. She completed a joint BA/MD program between
Rutgers University and the University of Medicine and Dentistry of New Jerseye
Robert Wood Johnson Medical School. Her pediatric residency and pediatric endo-
crinology fellowship were completed at Yale University, where she also obtained a
Ph.D. in Investigative Medicine through the Yale Graduate School of Arts &
Sciences.

Disclosures
LMN has received free supplies from Dexcom for investigator initiated studies. JLS reports
receiving consulting fees from Medtronic Diabetes and serving on advisory boards for Bigfoot
Biomedical, Cecelia Health, Eli Lilly (Nasal Glucagon), Insulet, and the T1D Fund.

References
[1] The Diabetes Control and Complications Trial Research Group. The effect of intensive
treatment of diabetes on the development and progression of long-term complications
in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993;
329(14):977e86.
[2] Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, et al. Modern-
day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes
control and complications trial/epidemiology of diabetes interventions and complica-
tions and Pittsburgh epidemiology of diabetes complications experience (1983e2005).
Archives of Internal Medicine 2009;169(14):1307e16.
[3] Hessler DM, Fisher L, Polonsky WH, Masharani U, Strycker LA, Peters AL, et al. Dia-
betes distress is linked with worsening diabetes management over time in adults with